Published in Haematologica on June 01, 2012
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. PLoS One (2013) 0.89
Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines. PLoS One (2014) 0.80
Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma. Cytometry B Clin Cytom (2015) 0.75
Characterization of clonogenic multiple myeloma cells. Blood (2003) 5.35
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res (2008) 3.57
Human neutrophils lose their surface Fc gamma RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood (1995) 2.39
Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J Biol Chem (2007) 2.25
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma. Blood (2007) 1.65
The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol (1998) 1.33
Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res (2010) 1.21
Pervanadate activation of intracellular kinases leads to tyrosine phosphorylation and shedding of syndecan-1. Biochem J (1996) 1.11
Shedding of heparan sulfate proteoglycan by stimulated endothelial cells: evidence for proteolysis of cell-surface molecules. J Cell Physiol (1996) 1.04
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood (2010) 2.33
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma]. Ugeskr Laeger (2009) 2.03
The transcriptional program of terminal granulocytic differentiation. Blood (2004) 1.80
Mutation update on the CHD7 gene involved in CHARGE syndrome. Hum Mutat (2012) 1.74
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol (2010) 1.57
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood (2004) 1.57
Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior. Nicotine Tob Res (2003) 1.51
Guidelines for the use of imaging in the management of myeloma. Br J Haematol (2007) 1.40
A bistable switch and anatomical site control Vibrio cholerae virulence gene expression in the intestine. PLoS Pathog (2010) 1.32
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood (2007) 1.32
Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood (2006) 1.27
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol (2005) 1.18
Identification of p.A684V missense mutation in the WFS1 gene as a frequent cause of autosomal dominant optic atrophy and hearing impairment. Am J Med Genet A (2011) 1.09
Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica (2004) 1.05
Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica (2010) 1.04
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood (2013) 0.98
Expression of HOXA genes in patients with multiple myeloma. Leuk Lymphoma (2004) 0.98
Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. Nicotine Tob Res (2003) 0.97
In multiple myeloma clonotypic CD38- /CD19+ / CD27+ memory B cells recirculate through bone marrow, peripheral blood and lymph nodes. Leuk Lymphoma (2004) 0.97
Smoking cessation or reduction with nicotine replacement therapy: a placebo-controlled double blind trial with nicotine gum and inhaler. BMC Public Health (2009) 0.96
Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol (2007) 0.92
Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol (2007) 0.92
Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma. Eur J Haematol (2014) 0.90
Highly glycosylated alpha1-acid glycoprotein is synthesized in myelocytes, stored in secondary granules, and released by activated neutrophils. J Leukoc Biol (2005) 0.90
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro. Eur J Haematol (2010) 0.89
High serum YKL-40 concentration is associated with severe bone disease in newly diagnosed multiple myeloma patients. Eur J Haematol (2007) 0.88
A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica (2009) 0.88
Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol (2010) 0.87
Pain and somatosensory findings in patients 3 years after total hip arthroplasty. Eur J Pain (2008) 0.86
Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration. Eur J Haematol (2013) 0.84
Development and progression of coronary artery calcification in long-term smokers: adverse effects of continued smoking. J Am Coll Cardiol (2013) 0.84
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma. Br J Haematol (2002) 0.84
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. Am J Hematol (2015) 0.84
Cognitive dysfunction following desflurane versus sevoflurane general anesthesia in elderly patients: a randomized controlled trial. Med Gas Res (2014) 0.82
Identification of ID-1 as a potential target gene of MMSET in multiple myeloma. Br J Haematol (2005) 0.82
Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma. Int J Cancer (2012) 0.82
Improved survival of multiple myeloma patients with late relapse after high-dose treatment and stem cell support, a population-based study of 348 patients in Denmark in 1994-2004. Eur J Haematol (2010) 0.81
Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis. Leuk Lymphoma (2012) 0.81
Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur J Haematol (2006) 0.81
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma. Int J Cancer (2009) 0.81
Regulation of the CD56 promoter and its association with proliferation, anti-apoptosis and clinical factors in multiple myeloma. Leuk Lymphoma (2009) 0.81
Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet (2007) 0.80
Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease. Leuk Lymphoma (2013) 0.79
No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer (2010) 0.79
Optic nerve histopathology in a case of Wolfram Syndrome: a mitochondrial pattern of axonal loss. Mitochondrion (2013) 0.79
The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP. Ann Hematol (2010) 0.78
Pain reduction after percutaneous vertebroplasty for myeloma-associated vertebral fractures. Dan Med J (2014) 0.78
Feasibility of fludarabine added to VAD during induction therapy in multiple myeloma: a randomised phase II-study. Eur J Haematol (2003) 0.78
Homoplasmy of the G7444A mtDNA and heterozygosity of the GJB2 c.35delG mutations in a family with hearing loss. Int J Pediatr Otorhinolaryngol (2010) 0.77
Clinical and preclinical validation of the serum free light chain assay: identification of the critical difference for optimized clinical use. Eur J Haematol (2012) 0.77
Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis: indications for different disease entities. Br J Haematol (2003) 0.77
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol (2014) 0.77
Two new cases with microdeletion of 17q23.2 suggest presence of a candidate gene for sensorineural hearing loss within this region. Am J Med Genet A (2011) 0.77
The phenotypic spectrum of dystonia in Mohr-Tranebjaerg syndrome. Mov Disord (2012) 0.77
Measurements of pericardial adipose tissue using contrast enhanced cardiac multidetector computed tomography--comparison with cardiac magnetic resonance imaging. Int J Cardiovasc Imaging (2013) 0.77
Rapidly progressive renal disease as part of Wolfram syndrome in a large inbred Turkish family due to a novel WFS1 mutation (p.Leu511Pro). Eur J Med Genet (2011) 0.76
GJB2 (Connexin-26) mutations are not frequent among hearing impaired patients in east Greenland. Int J Audiol (2012) 0.76
Biological variation of free light chains in serum. Clin Chim Acta (2013) 0.75
FGFR3 dysregulation and clinical outcome in myeloma. Br J Haematol (2003) 0.75
A rare cause of severe hepatomegaly with an improving outcome. BMJ Case Rep (2014) 0.75
Genetic variants in the P2RX7 gene are associated with risk of multiple myeloma. Eur J Haematol (2014) 0.75
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma. Br J Haematol (2010) 0.75
Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol (2013) 0.75
[Polyneuropathy associated with monoclonal gammopathy of undetermined significance]. Ugeskr Laeger (2012) 0.75
Upregulated MCL1 mRNA expression in multiple myeloma lacks association with survival. Br J Haematol (2008) 0.75
Polymorphisms in the heparanase gene in multiple myeloma association with bone morbidity and survival. Eur J Haematol (2014) 0.75
The relationship of intravenous dextrose administration during emergence from anesthesia to postoperative nausea and vomiting: a randomized controlled trial. Anesth Analg (2013) 0.75
[Determination of light chains in serum]. Ugeskr Laeger (2010) 0.75
[A syndrome of chronic ataxic polyneuropathy, ophtalmoplegia, IgM paraprotein, cold agglutinins and anti-disialosyl antibodies can cause diplopia in patients with chronic sensory polyneuropathy]. Ugeskr Laeger (2012) 0.75